Stockscreener 앱 받기
0.9123
5.07%
0.0469
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
Piper Sandler reiterates Overweight on Tenaya stock, $40 target - Investing.com
TNYATenaya Therapeutics Inc Options - Finviz
Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st
TNYA News | TENAYA THERAPEUTICS INC (NASDAQ:TNYA) - ChartMill
Tenaya Therapeutics (NASDAQ: TNYA) exits Union City manufacturing lease, shifts to CDMO - Stock Titan
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Investing News Network
Tenaya Therapeutics appoints Eric Hyllengren as CFO By Investing.com - Investing.com Australia
Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026 - marketscreener.com
Tenaya Therapeutics Appoints New Chief Financial Officer - TipRanks
Eric Hyllengren to lead finances at Tenaya Therapeutics (NASDAQ: TNYA) - Stock Titan
Tenaya Therapeutics appoints Eric Hyllengren as CFO - Investing.com
Press Release: Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - Moomoo
Price to book forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
Price to sales forward of Tenaya Therapeutics, Inc. – NASDAQ:TNYA - TradingView
symbol__ Stock Quote Price and Forecast - CNN
TENAYA THERAPEUTICS INC (TNYA) Stock Chart - ChartMill
Tenaya Therapeutics Inc (TNYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tenaya Therapeutics (TNYA) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Tenaya Therapeutics Inc (TNYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Institutional Confidence - TradingKey
Tenaya Therapeutics Inc (TNYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tenaya Therapeutics Inc (TNYA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tenaya Therapeutics Inc (TNYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tenaya Therapeutics Inc (TNYA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tenaya Therapeutics Inc (TNYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tenaya Therapeutics Inc (TNYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tenaya Therapeutics (TNYA) Q1 2026 Earnings: EPS Miss Reflects R&D Investment as Company Advances PipelineNegative Surprise Momentum - newsline.com
TNYA Q1 2026 Earnings: Slightly Wider-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineMid-Term Outlook - newsline.com
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
Morgan Stanley Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $2 - Moomoo
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $2 to $4 - Moomoo
TNYA: Strong clinical progress and regulatory momentum for gene therapy and small molecule programs - TradingView
LifeSci Capital Maintains Tenaya Therapeutics(TNYA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCMSlideshow (NASDAQ:TNYA) 2026-06-03 - Seeking Alpha
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in... - markets.businessinsider.com
Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms - TradingView
Tenaya reports interim data from gene therapy trial for rare heart condition - Investing.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms - The Manila Times
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Sym - StreetInsider
Gene therapy eases genetic heart condition in small Tenaya trial - Stock Titan
Tenaya Therapeutics to Announce New Interim Data from MyPEAK-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - Investing News Network
Tenaya to present gene therapy trial data Wednesday By Investing.com - Investing.com South Africa
Tenaya to present gene therapy trial data Wednesday - Investing.com
Tenaya Therapeutics to Report Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 Gene Therapy for HCM on June 3, 2026 - Quiver Quantitative
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 - The Manila Times
Tenaya Therapeutics to Announce New Interim Data from - GlobeNewswire
Tenaya Therapeutics, Inc. Announces Amended and Restated 2021 Equity Incentive Plan and SEC Filing Details - Minichart
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike - Stock Titan
Tenaya director granted options for 120,000 shares | TNYA Insider Trading - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) awards director 120,000 options at $0.7989 - Stock Titan
Tenaya (TNYA) director receives 120K stock options at $0.7989 - Stock Titan
Tenaya Therapeutics (TNYA) director June Lee granted 120,000 stock options - Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options grant - Stock Titan
Tenaya Therapeutics (NASDAQ: TNYA) boosts share pool in revised equity plan - Stock Titan
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 - Investing News Network
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference on May 29, 2026 - geneonline.com
Tenaya Therapeutics to present at Jefferies Global Healthcare Conference 2026 in June - Pluang
1.88%
2.71%
자본화:
|
볼륨(24시간):